Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor

por Li, Xiaoyan, Shelton, Mark J, Wang, Jing, Meade, Julie, Ruiz‐Soto, Rodrigo
Publicado 2022

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models()...

por Ponte, Jose F., Ab, Olga, Lanieri, Leanne, Lee, Jenny, Coccia, Jennifer, Bartle, Laura M., Themeles, Marian, Zhou, Yinghui, Pinkas, Jan, Ruiz-Soto, Rodrigo
Publicado 2016

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the F...

por Martin, Lainie P., Konner, Jason A., Moore, Kathleen N., Seward, Shelly M., Matulonis, Ursula A., Perez, Raymond P., Su, Ying, Berkenblit, Anna, Ruiz-Soto, Rodrigo, Birrer, Michael J.
Publicado 2017

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

por Janku, Filip, Abdul Razak, Albiruni R., Chi, Ping, Heinrich, Michael C., von Mehren, Margaret, Jones, Robin L., Ganjoo, Kristen, Trent, Jonathan, Gelderblom, Hans, Somaiah, Neeta, Hu, Simin, Rosen, Oliver, Su, Ying, Ruiz-Soto, Rodrigo, Gordon, Michael, George, Suzanne
Publicado 2020

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

por Smith, Bryan D., Kaufman, Michael D., Wise, Scott C., Ahn, Yu Mi, Caldwell, Timothy M., Leary, Cynthia B., Lu, Wei-Ping, Tan, Gege, Vogeti, Lakshminarayana, Vogeti, Subha, Wilky, Breelyn A., Davis, Lara E., Sharma, Maitreyi, Ruiz-Soto, Rodrigo, Flynn, Daniel L.
Publicado 2021

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

por Bauer, Sebastian, Heinrich, Michael C., George, Suzanne, Zalcberg, John R., Serrano, César, Gelderblom, Hans, Jones, Robin L., Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Meade, Julie, Su, Ying, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret, Schöffski, Patrick
Publicado 2021

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

por Schöffski, Patrick, George, Suzanne, Heinrich, Michael C., Zalcberg, John R., Bauer, Sebastian, Gelderblom, Hans, Serrano, César, Jones, Robin L., Attia, Steven, D’Amato, Gina, Chi, Ping, Reichardt, Peter, Becker, Claus, Shi, Kelvin, Meade, Julie, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret
Publicado 2022

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

por Zalcberg, John R., Heinrich, Michael C., George, Suzanne, Bauer, Sebastian, Schöffski, Patrick, Serrano, César, Gelderblom, Hans, Jones, Robin L., Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Somaiah, Neeta, Meade, Julie, Reichert, Vienna, Shi, Kelvin, Sherman, Matthew L., Ruiz‐Soto, Rodrigo, von Mehren, Margaret, Blay, Jean‐Yves
Publicado 2021

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

por Bauer, Sebastian, Jones, Robin L., Blay, Jean-Yves, Gelderblom, Hans, George, Suzanne, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Su, Ying, Meade, Julie, Wang, Tao, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C.
Publicado 2022